149809-43-8

Product Details:

CasNo： 149809-43-8

Molecular Formula： C21H21F2N3O4S

Appearance： White to Orange to Green powder to crystal

Purity： 99%

Synonyms: Posaconazole Impurity 53; ((3S,5R)-5-((1H-1,2,4-triazol-1-yl)Methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)Methyl 4-Methylbenzenesulfonate; Posaconazole InterMediates; 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[[(4-Methylphenyl)sulfonyl]oxy]Methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; (5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)Methyltetrahydrofuran-3-ylMethyl ester- (POA); Toluene-4-sulfonica cid 5-(2,4-difluoro-phenyl)-5-[1,2,4]triazol-1-ylMethyl-tetrahydro-furan-3-ylMethyl ester; ((3R,5R)-5-((1H-1,2,4-triazol-1-yl)Methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)Methyl 4-Methylbenzenesulfonate
Melting point: 100-102°C
Boiling point: 608.1±65.0°C
Density: 1.40 g/cm3
Solubility: slightly sol. in Chloroform
Pka: 2.75±0.10
Form: powder to crystal
Color: White to Orange to Green
Storage temp.: -20°C Freezer, Under Inert Atmosphere

Description:
(5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester is a pharmaceutical intermediate ingredient for Posaconazole is one of the newest triazole antifungal agents approved by the FDA for the prevention of invasive Aspergillus and Candida infections in immunocompromised patients. Such patients include haematopoietic stem cell transplant patients with graft-versus-host disease and patients with haematological malignancies undergoing chemotherapy.

Uses:

Posaconazole intermediate. Antifungal agent.